Hikma - Hikma Pharmaceuticals PLC (HIK.L)

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

H

H

Hikma

Balita

Reuters - 2 araw ang nakaraan

Danske Bank, Lotus Bakeries NV, Vesuvius

EUROPE RESEARCH ROUNDUP-Danske Bank, Lotus Bakeries NV, Vesuvius Aug 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Lotus Bakeries NV and Vesuvius, on Tuesday. HIGHLIGHTS * Abrdn Plc ABDN.L : Morgan Stanley raises target price to 160p from 149p * Danske Bank DANSKE.CO : Morgan Stanley initiates coverage with overweight rating * Lotus Bakeries NV LOTB.BR : Berenberg raises target price to EUR 10,300 from EUR 9,000 *

Reuters - 6 araw ang nakaraan

Ashtead Group, Beazley, Entain

EUROPE RESEARCH ROUNDUP-Ashtead Group, Beazley, Entain Aug 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Group, Beazley and Entain, on Friday. HIGHLIGHTS * Ashtead Group Plc AHT.L : KeyBanc initiates coverage with sector weight rating * Beazley Plc BEZG.L : Berenberg raises target price to 950p from 880p * Entain Plc ENT.L : Deutsche Bank cuts target price to 958p from 1,089p * Rheinmetall AG RHMG.DE : Morgan Stanley up

Reuters - 6 araw ang nakaraan

London's FTSE 100 ends lower as top companies trade ex-dividend

UPDATE 1-London's FTSE 100 ends lower as top companies trade ex-dividend For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window FTSE 100, FTSE 250 down 0.3% Heavyweights trade without dividend entitlement Beazley upgrades 2024 combined ratio forecast, shares surge Updated at 1425 GMT By Purvi Agarwal and Shubham Batra Aug 8 (Reuters) - London's FTSE 100 slipped on Thursday, tracking global market sentiment, while investors assessed corporate up

Reuters - 1 linggo ang nakaraan

STOXX 600 recovers early losses on US jobs data relief

UPDATE 2-STOXX 600 recovers early losses on US jobs data relief For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Novo rebounds on positive read-across from Lilly Siemens jumps after profit beat Allianz rises on Q2 beat Deutsche Telekom up after increase in Q2 core earnings STOXX 600 up 0.1% Updates at 1600 GMT By Ankika Biswas and Pranav Kashyap Aug 8 (Reuters) - Europe's benchmark stock index recouped early losses to close slightly highe

Reuters - 1 linggo ang nakaraan

That unwind feeling

LIVE MARKETS-That unwind feeling STOXX 600 down 1.1% Volatility above 23 Banks, tech down Some UK earnings please Nasdaq futures fall Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com THAT UNWIND FEELING European shares got off to a lower start on Thursday, bringing about the feeling that the yen carry trade unwind is not over yet.

Reuters - 1 linggo ang nakaraan

UK's Hikma gains on upbeat annual outlook, sturdy H1 performance

BUZZ-UK's Hikma gains on upbeat annual outlook, sturdy H1 performance ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 5.3% at 1,937p ** Stock among top gainers in the FTSE 100 index .FTSE ** Co forecasts its annual revenue to grow in the range of 6% to 8%, up from previous outlook of 4% to 6% ** Sees FY core operating profit of $700 m

Reuters - 1 linggo ang nakaraan

Hikma Sees FY Group Core Oper Profit Of $700 Mln To $730 Mln

BRIEF-Hikma Sees FY Group Core Oper Profit Of $700 Mln To $730 Mln Aug 8 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HY INTERIM DIVIDEND OF 32 CENTS PER SHARE, UP 28% UPGRADES GROUP GUIDANCE SEES FY GROUP REVENUE GROWTH OF 6% TO 8%, UP FROM 4% TO 6% SEES FY GROUP CORE OPERATING PROFIT OF $700 MILLION TO $730 MILLION, UP FROM $660 MILLION TO $700

Reuters - 1 linggo ang nakaraan

UK Stocks-Factors to watch on August 8

UK Stocks-Factors to watch on August 8 Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.5%. * GSK: The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.

Reuters - 1 linggo ang nakaraan

NZ's AFT Pharmaceuticals gains on deal to distribute pain management tablets in US

BUZZ-NZ's AFT Pharmaceuticals gains on deal to distribute pain management tablets in US ** Shares of AFT Pharmaceuticals AFT.NZ rise as much as 1.6% to NZ$3.15, their highest level since June 18 ** Pharmaceutical co signs agreement with Hikma Pharmaceuticals USA to distribute its patented COMBOGESIC tablets, used for adult pain management, to selec

Reuters - 2 linggo ang nakaraan

UK corporate earnings week ahead

DIARY-UK corporate earnings week ahead Aug 2 (Reuters) - Diary of U.K (.FTSE) corporate earnings for the week ahead UK EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 06-Aug-2024 06:00 IHG.L InterContinental Hotels Group PLC Half Year 2024 InterContinental Hotels Group PLC Earnings Release 07-Aug-2024 06:00 GLEN.L Glencore PLC Half Year 2024 Glencore PLC Earnings Release 07-Aug-2024 06:00 CCH.L Coca Cola HBC AG Half Year 2024 Coca Cola HBC AG Earnings Release 08-Aug-2024 NTS HIK

Reuters - 3 linggo ang nakaraan

Hikma Pharmaceuticals Extends Voluntary Nationwide Recall Of One Lot Of Acetaminophen Injection, US FDA Says

BRIEF-Hikma Pharmaceuticals Extends Voluntary Nationwide Recall Of One Lot Of Acetaminophen Injection, US FDA Says July 22 (Reuters) - Food and Drug Administration: FDA: HIKMA PHARMACEUTICALS USA INC. EXTENDS VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF ACETAMINOPHEN INJECTION, 1000MG/100ML, (10MG/ML) BAGS FDA-HIKMA RECALL DUE TO INDIVIDUAL UNIT OF AC

Reuters - 2 buwan ang nakaraan

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

UPDATE 2-Teva launches generic version of Novo Nordisk's diabetes drug Victoza Adds details on Victoza in paragraphs 4 to 6 June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it had launched a generic version of Novo Nordisk's NOVOb.CO Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand .

Reuters - 2 buwan ang nakaraan

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

Teva launches generic version of Novo Nordisk's diabetes drug Victoza June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's NOVOb.CO drug Victoza to treat patients with type 2 diabetes. The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals' HIK.L version of Victoza, according to the agency's website.

Reuters - 2 buwan ang nakaraan

Hikma Acquires Xellia’S Assets

BRIEF-Hikma Acquires Xellia’S Assets June 17 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HIKMA PHARMACEUTICAL - HIKMA ACQUIRES XELLIA’S ASSETS HIKMA: HIKMA WILL PAY A CASH CONSIDERATION OF $135 MILLION, AND AN ADDITIONAL CONTINGENT CONSIDERATION OF UP TO $50 MILLION HIKMA: ACQUISITION WILL ADD EIGHT APPROVED AND MARKETED INJECTABLE PRODUCTS T

Reuters - 2 buwan ang nakaraan

UK's Hikma gains as Citi raises target price

BUZZ-UK's Hikma gains as Citi raises target price ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 3% at 1,989p ** Stock is top pct gainer on FTSE 100 index .FTSE ** Brokerage Citigroup raises target price to 2845p from 2770p ** Research firm IQVIA's data on HIK highly encouraging; we go to the top-end of forecast range - Citi ** Hikma

Reuters - 2 buwan ang nakaraan

Banco Bpm, Firstgroup, Xps Pensions

EUROPE RESEARCH ROUNDUP-Banco Bpm, Firstgroup, Xps Pensions June 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco Bpm, Firstgroup and Xps Pensions Group, on Tuesday. HIGHLIGHTS * Banco Bpm BAMI.MI : Morgan Stanley cuts to equal weight from overweight * Firstgroup Plc FGP.L : RBC raises target price to 200p from 195p * JCDecaux SE JCDX.PA : Deutsche Bank cuts to hold from buy * Next Plc NXT.L : HSBC raises target price to 9,

Reuters - 3 buwan ang nakaraan

Egypt receives second payment of $14 bln from UAE for Ras al-Hikma project

REFILE-UPDATE 1-Egypt receives second payment of $14 bln from UAE for Ras al-Hikma project Specifies location of peninsula 200 km from Alexandria in paragraph 2 CAIRO, May 15 (Reuters) - Egypt received $14 billion from the United Arab Emirates on Wednesday as a second payment for the development of Ras al-Hikma peninsula, a cabinet statement said.

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.